Helvetic

Helvetic Biopharma is a Swiss biotechnology company specializing in the development, manufacturing, and commercialization of high-quality biologics and biosimilars. Headquartered in Geneva, the company focuses on expanding global access to essential therapies for oncology and inflammatory diseases through its robust protein engineering and cell line development capabilities. Helvetic Biopharma operates as both a product developer and a contract development and manufacturing organization (CDMO), offering end-to-end services from early-stage R&D to large-scale GMP production. Its pipeline features biosimilar versions of blockbuster monoclonal antibodies, including adalimumab and bevacizumab, aimed at providing cost-effective alternatives in emerging and established markets. The company leverages advanced mammalian cell culture technologies to ensure high yields and therapeutic consistency across its portfolio.